HF 1020

Drug Profile

HF 1020

Alternative Names: Enterotoxin B; EtxB

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Bristol
  • Developer Trident Pharmaceuticals
  • Class Antiallergics; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Bacterial proteins; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 10 Sep 2010 Preclinical trials in Inflammation in United Kingdom (unspecified route)
  • 11 Jul 2007 HF 1020 is available for licensing worldwide (http://www.hunter-fleming.com)
  • 11 Jan 2002 Preclinical development for Allergic asthma in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top